Pharmacoeconomic considerations with statin therapy

Katie M. Speidel, Daniel E. Hilleman

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Statins have been shown to reduce morbidity and mortality in patients with and without coronary heart disease, and in patients with elevated and normal or average cholesterol levels. Economic evaluations of these mortality trials have demonstrated statins to be cost-effective. As these trials were placebo comparisons, their results are now of limited use in guiding the drug therapy selection process. The more relevant questions today are focused on ways of optimising statin therapy. More recent studies have found that more intensive statin therapy, using high doses of these agents that produce substantially greater reductions in low-density lipoprotein cholesterol, are associated with greater benefit than less intensive statin therapy. These trials suggest that statins with greater efficacy in reducing low-density lipoprotein cholesterol, would be preferred over less effective statins. So far, economic analyses of these comparative studies have not been published. These economic studies are needed to support formulary and drug therapy selection decisions regarding statins.

Original languageEnglish
Pages (from-to)1291-1304
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume7
Issue number10
DOIs
StatePublished - Jul 2006

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmaceutical Economics
Therapeutics
LDL Cholesterol
Economics
Formularies
Drug Therapy
Mortality
Cost-Benefit Analysis
Coronary Disease
Cholesterol
Placebos
Morbidity
Costs and Cost Analysis

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacoeconomic considerations with statin therapy. / Speidel, Katie M.; Hilleman, Daniel E.

In: Expert Opinion on Pharmacotherapy, Vol. 7, No. 10, 07.2006, p. 1291-1304.

Research output: Contribution to journalReview article

@article{51ab062bd18043b9946a2a94b7edca92,
title = "Pharmacoeconomic considerations with statin therapy",
abstract = "Statins have been shown to reduce morbidity and mortality in patients with and without coronary heart disease, and in patients with elevated and normal or average cholesterol levels. Economic evaluations of these mortality trials have demonstrated statins to be cost-effective. As these trials were placebo comparisons, their results are now of limited use in guiding the drug therapy selection process. The more relevant questions today are focused on ways of optimising statin therapy. More recent studies have found that more intensive statin therapy, using high doses of these agents that produce substantially greater reductions in low-density lipoprotein cholesterol, are associated with greater benefit than less intensive statin therapy. These trials suggest that statins with greater efficacy in reducing low-density lipoprotein cholesterol, would be preferred over less effective statins. So far, economic analyses of these comparative studies have not been published. These economic studies are needed to support formulary and drug therapy selection decisions regarding statins.",
author = "Speidel, {Katie M.} and Hilleman, {Daniel E.}",
year = "2006",
month = "7",
doi = "10.1517/14656566.7.10.1291",
language = "English",
volume = "7",
pages = "1291--1304",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Pharmacoeconomic considerations with statin therapy

AU - Speidel, Katie M.

AU - Hilleman, Daniel E.

PY - 2006/7

Y1 - 2006/7

N2 - Statins have been shown to reduce morbidity and mortality in patients with and without coronary heart disease, and in patients with elevated and normal or average cholesterol levels. Economic evaluations of these mortality trials have demonstrated statins to be cost-effective. As these trials were placebo comparisons, their results are now of limited use in guiding the drug therapy selection process. The more relevant questions today are focused on ways of optimising statin therapy. More recent studies have found that more intensive statin therapy, using high doses of these agents that produce substantially greater reductions in low-density lipoprotein cholesterol, are associated with greater benefit than less intensive statin therapy. These trials suggest that statins with greater efficacy in reducing low-density lipoprotein cholesterol, would be preferred over less effective statins. So far, economic analyses of these comparative studies have not been published. These economic studies are needed to support formulary and drug therapy selection decisions regarding statins.

AB - Statins have been shown to reduce morbidity and mortality in patients with and without coronary heart disease, and in patients with elevated and normal or average cholesterol levels. Economic evaluations of these mortality trials have demonstrated statins to be cost-effective. As these trials were placebo comparisons, their results are now of limited use in guiding the drug therapy selection process. The more relevant questions today are focused on ways of optimising statin therapy. More recent studies have found that more intensive statin therapy, using high doses of these agents that produce substantially greater reductions in low-density lipoprotein cholesterol, are associated with greater benefit than less intensive statin therapy. These trials suggest that statins with greater efficacy in reducing low-density lipoprotein cholesterol, would be preferred over less effective statins. So far, economic analyses of these comparative studies have not been published. These economic studies are needed to support formulary and drug therapy selection decisions regarding statins.

UR - http://www.scopus.com/inward/record.url?scp=34447098428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447098428&partnerID=8YFLogxK

U2 - 10.1517/14656566.7.10.1291

DO - 10.1517/14656566.7.10.1291

M3 - Review article

VL - 7

SP - 1291

EP - 1304

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 10

ER -